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Abstract
Background: Fiducial markers are the superior method to compensate for interfractional motion in liver SBRT.
However this method is invasive and thereby limits its application range. In this retrospective study, the
compensation method for the interfractional motion using fiducial markers (gold standard) was compared
to a new non-invasive approach, which does rely on the organ motion of the liver and the relative tumor
position within this volume.
Methods: We analyzed six patients (3 m, 3f) treated with SBRT in 2014. After fiducial marker implantation, all
patients received a treatment CT (free breathing, without abdominal compression) and a 4D-CT (consisting of
10 respiratory phases). For all patients the gross tumor volumes (GTVs), internal target volume (ITV), planning
target volume (PTV), internal marker target volumes (IMTVs) and the internal liver target volume (ILTV) were
delineated based on the CT and 4D-CT images. CBCT imaging was used for the standard treatment setup
based on the fiducial markers. According to the patient coordinates the 3 translational compensation values
(tx, ty, tz) for the interfractional motion were calculated by matching the blurred fiducial markers with the
corresponding IMTV structures. 4 observers were requested to recalculate the translational compensation
values for each CBCT (31) based on the ILTV structures. The differences of the translational compensation
values between the IMTV and ILTV approach were analyzed.
Results: The magnitude of the mean absolute 3D registration error with regard to the gold standard overall
patients and observers was 0.50 cm ± 0.28 cm. Individual registration errors up to 1.3 cm were observed. There
was no significant overall linear correlation between the respiratory motion and the registration error of the
ILTV approach.
Conclusions: Two different methods to calculate the translational compensation values for interfractional
motion in stereotactic liver therapy were evaluated. The registration accuracy of the ILTV approach is mainly
limited by the non-rigid behavior of the liver and the individual registration experience of the observer. The
ILTV approach lacks the accuracy that would be desired for stereotactic radiotherapy of the liver.
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Background
Stereotactic body radiation therapy (SBRT) has emerged
as an alternative in treatment of hepatocellular carcin-
oma (HCC) [1–4] and oligometastatic liver disease [5–7]
over the past decade. Nevertheless, SBRT of liver malig-
nancies is challenging due to the high biologically effec-
tive doses and the uncertainty of the tumor position
resulting from a combination of a) intrafractional quasi-
periodic motion resulting from the patient’s respiration,
b) intrafractional motion (e.g., baseline shifts due to
relaxation) and c) interfractional motion resulting from
e.g., different fillings of the gastrointestinal tract and
patient positioning.
In general, uncertainties resulting from intrafractional
motion are minimized (e.g., abdominal compression,
breath hold, gating) and compensated by specific margin
concepts (e.g., ITV). Interfractional motion, which leads
to a systematic shift of the tumor position, is usually
managed by image guidance modalities (e.g., CBCT,
ultrasound). However, imaging of liver malignancies and
hereby the compensation of interfractional motion is
challenging.
Regularly, the skeletal anatomy is inadequate for SBRT
positioning [8] and the target itself may not be detec-
table in CT or CBCT. Hence only a surrogate of the
exact tumor position can be visualized (e.g., fiducial
markers [9]). On the one hand, it has been shown that
the implantation of fiducial markers next to the tumor
allows a high-precision tumor radiation setup [10, 11],
on the other hand the implantation of fiducial markers
is naturally an invasive procedure that is not applicable
for all patients and thereby limits the application range
of SBRT. Furthermore, fiducial markers compromise
the image quality of the planning CT [12, 13] and make
the tumor delineation more difficult. It is obvious
that a different surrogate of the exact tumor position
is desirable.
In this retrospective study, the compensation method
for the interfractional motion using fiducial markers
(gold standard) was compared to a new approach which
does not rely on fiducial markers but on the organ mo-




Starting in 2014 this retrospective study includes 6 patients
(3f, 3 m), that suffered from HCC (5/6) and oligometa-
static disease (1/6). Prescribed doses and fractionation
depended on localization, size of the lesion, mobility and
liver function. One patient was not able to complete the
radiotherapy course due to an accident resulting in a
humerus fracture.
Preparation and treatment workflow
All patients received a magnetic resonance imaging
(MRI) scan and fiducial markers were implanted prior to
the planning CT acquisition. Patient positioning for
CT imaging and treatment was realized by the use of a
vacuum cushion in combination with the WingSTEP
(Elekta AB, Sweden). The patients were instructed to
breathe freely, and respiration was not restricted by
any device. Afterwards, a treatment planning CT and a
4D-CT were acquired. The spatial resolution of the
treatment CT (1.074 mm × 1.074 mm × 3.0 mm) was
equal to the resolution of the 4D-CT, which consisted
of 10 respiratory phases. For each patient an internal
target volume (ITV) was delineated containing the
gross tumor volume (GTV) outlines of the 10 respira-
tory phases enlarged by an isotropic margin of 6 mm.
Furthermore each fiducial marker was delineated in all
respiratory phases and a covering volume (hull) with-
out any additional margin was generated, hereafter re-
ferred to as “internal marker target volume” (IMTV).
In analogy to the IMTV a second structure set has
been created for this study, including only an “internal
liver target volume” (ILTV). For the daily treatment, all
patients were setup by using CBCT imaging. Due to
the slow temporal resolution of the CBCT, fiducial
markers were blurred over several respiration cycles
similar to the contoured IMTVs generated from the
patient’s 4D-CT. According to the patient coordinates
defined in the DICOM standard, the 3 translational
compensation values (tx, ty, tz) for the interfractional
motion were calculated by matching the blurred fidu-
cial markers with the corresponding IMTV structures.
Afterwards the compensation values were sent to a ro-
botic couch to correct the daily patient position.
Recalculation of the compensation values using different
approaches
In this retrospective study, 4 observers were requested
to recalculate the translational compensation values. The
virtual patient setup was done in MOSAIQ (Elekta AB,
Sweden), using the image registration module. Table 1
gives an overview of the patient data.
Patient setup using fiducial markers
The first method to recalculate the translational com-
pensation values followed a workflow similar to the
method used for the daily treatment setup. For each
available CBCT a coarse rigid preregistration has been
calculated, based on the gray values in CBCT and the
initial planning CT. Due to the differences in the daily
patient anatomy a second registration step was required.
For that reason a manual rigid registration was applied
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with a strong focus to optimize the correlation between
the blurred fiducial markers in the CBCT and the corre-
sponding IMTV structures (see Fig 1a). For each CBCT
the resulting translational compensation values were
calculated once and served as a gold standard for the
second approach.
Patient setup using organ motion of the liver
The second method also makes use of a coarse rigid pre-
registration based on the image intensities. But the final
manual registration step relies on the ILTV structure that
was generated for each patient. Not only the fiducial
markers but also the whole liver volume appears to be
blurred in the daily CBCT. Therefore the 4 observers were
requested to optimize the correlation between the blurred
liver volume and the ILTV structure generated from the pa-
tient’s 4D-CT (see Fig 1b). Again, the resulting translational
compensation components were recorded for each CBCT.
Results
In total, 31 different CBCT data sets from 6 different pa-
tients were registered by 4 observers using the second ap-
proach. As a result of each registration the difference
(registration error) of the translational compensation
values between the actual registration and the gold stand-
ard has been calculated. All values were recorded in cm.
Thereby the dx component denotes the left-right, the dy
component denotes the anterior-posterior and the dz
component denotes the superior-inferior deviation be-
tween the actual registration and the registration based on
the fiducial markers. Besides, an overall deviation magni-
tude from all three components was calculated (see Fig 2).
The smallest standard deviation of the registration
error over all patients and observers can be observed in
the dx component (0.24 cm), followed by standard
deviation of the dy (0.33 cm) and the dz component
(0.41 cm). The magnitude of the mean absolute 3D
registration error over all patients and observers was
0.50 cm ± 0.28 cm. Although the standard deviations of
a single component imply a small registration error,
individual registration errors of up to 1.3 cm were
observed. The evaluation of the data by the individual
observers is shown in Table 2.
The dx, dy and dz components of the registration
errors increase in the named order. Hence a relation
between the magnitude of respiratory induced motion
and the components of the registration error was as-
sumed. From [14] it is known that the organ motion
of the liver in the superior-inferior direction is bigger
than in the other directions. As a consequence the
uncertainty of registration in that direction should
also be higher than in the other directions. To check
Table 1 Overview of the analyzed patient data
Patient A B C D E F
Tumor type Olig. met. HCC HCC HCC HCC HCC
Tumor localization Seg. VI Seg. VIII Seg. II Seg. I Seg. V/VIII Seg. I + VIII
[GTV] = cc 3.5 16.6 23.9 72.7 12.9 1.4
[ITV] = cc 14.1 48.1 55.6 133.2 32.5 3.1
[PTV] = cc 43.7 109.0 115.1 230.0 75.5 20.9
# fiducial markers 3 2 1 1 1 3
# available CBCTs 7 2 9 5 4 4
Data sets 1–7 8–9 10–18 19–23 24–27 28–31
Fig. 1 a example of a registration based on fiducial markers (green); b Example of a registration based on the organ motion of the liver (red)
displayed at different window/level settings
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Fig. 2 Components and magnitude of all calculated registration errors for all data sets and all observers
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for a correlation between the respiratory motion and
the registration errors for each fiducial marker the
trajectory of its center of mass (COM) was calculated
from the 4D-CT data (Table 3). If there is a correlation
between respiratory induced motion and the registration
error, it will be reasonable to reduce the respiratory mo-
tion by additional actions (e.g., abdominal compression).
Figure 3 shows the error magnitude of each com-
ponent plotted against the movement of the fiducial
markers (COM) in the same direction. The plot does
not show a significant overall linear correlation between
the respiratory motion and the registration error. The
coefficients of determination (R2) are low and vary be-
tween different observers (0.0003–0.4929).
Discussion
Liver SBRT is a highly effective locally ablative technique
and may be applied non-invasively. Due to quasiperiodic
motion of the liver and its partially non-rigid behavior,
fiducial markers are regarded as gold standard when
delivering high radiation dose to malignant liver lesions.
Within this study, we examined whether fiducial marker
implantation was really necessary to account for all
different modes of motion. A soft-tissue approach was
chosen employing a liver ITV concept (ILTV) being
coregistered to a CBCT blurred liver anatomy; if the
liver was comparable to a rigid body, this should result
in comparable results to the implanted fiducial markers.
We included 31 different datasets from 6 patients in
this study and found that the accuracy of the motion
based patient setup is limited to 3D registration errors
of 0.23 ± 0.05 cm up to 0.98 ± 0.08 cm depending on a
specific patient and observer. The largest registration er-
rors were observed in the cranio-caudal direction which
is the major direction of liver motion. A componentwise
comparison of the registration errors and the
corresponding motion extents led to the assumption of a
correlation between the motion extent and the registra-
tion error. However, this assumption could not be
proved since only poor coefficients of determination
were found for a linear regression. Therefore it is
questionable whether abdominal compression is able
to improve the registration results in an organ motion
based patient setup significantly.
In addition to the respiratory motion, the low image
contrast of soft-tissues in CBCT makes it difficult to cor-
rect the patient’s position using the organ motion based
patient setup. Hence, the experience of the individual
observer has been identified as a main parameter of the
registration accuracy.
In a similar study [15], it has been shown, that the
soft-tissue-based image guidance with consideration of
the 4D breathing motion (organ motion based patient
setup) is able to increase the accuracy of treatment
compared with stereotactic positioning or image guided
radiotherapy without 4D imaging. However, in compari-
son to the fiducial marker based setup (IMTV), which is
supposed to be the superior technique to predict the
tumor position compared to other surrogates [11, 16],
the registration errors observed in this study imply that
the organ motion based patient setup (ILTV) requires
adapted safety margins larger than the ones used in a
fiducial marker setup.
In general the accuracy of the organ motion based pa-
tient setup is limited by the fact that the liver itself does
not behave like a rigid object, but is deformed under the
influence of respiration. At least three different types of
motion were identified in [14], for singular points in the
liver volume. For this reason a singular rigid registration
of the whole liver will result in different, unknown regis-
tration errors depending on the location inside the liver.
Above all we found a good agreement of the motion ex-
tents of different spots inside the liver compared to [14].
Conclusions
A new method to compensate for interfractional motion,
based on the organ motion of the liver, was compared to
the patient setup using fiducial markers. The latter
method served as gold standard. It has been shown that
a rigid registration based on the organ motion of the
liver lacks the accuracy that would be desired for
Table 3 Respiratory induced motion of fiducial markers
calculated from 4D-CT
Patient A B C D E F
[Magnitude of motion] cm cm cm cm cm cm
left-right 0.19 0.17 0.16 0.16 0.13 0.08
anterior-posterior 0.46 0.86 0.51 0.19 0.53 0.52
superior-inferior 1.45 1.67 0.79 0.74 1.15 1.52
Table 2 Magnitudes of the 3D registration error by the individual observers
Patient A B C D E F
[Magnitude of registration error] cm cm cm cm cm cm
Observer 1 0.42 ± 0.19 0.23 ± 0.05 0.23 ± 0.10 0.36 ± 0.13 0.30 ± 0.10 0.46 ± 0.06
Observer 2 0.74 ± 0.16 0.30 ± 0.20 0.24 ± 0.11 0.40 ± 0.14 0.66 ± 0.38 0.66 ± 0.13
Observer 3 0.70 ± 0.21 0.97 ± 0.05 0.42 ± 0.21 0.34 ± 0.07 0.64 ± 0.23 0.86 ± 0.19
Observer 4 0.65 ± 0.30 0.90 ± 0.10 0.53 ± 0.25 0.52 ± 0.19 0.29 ± 0.19 0.98 ± 0.08
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stereotactic radiotherapy of the liver. The registration
accuracy is mainly limited by the non-rigid behavior of
the liver and the individual registration experience of the
observer. Whenever possible, the preferred method to
setup the patient and correct for interfractional changes
or motion is to place fiducial markers next to the target
location and coregister the estimated IMTV to the daily
CBCT data.
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